Our patented technology simultaneously analyzes multiple biomarkers in tumors in order to predict patient response to one or more targeted therapies. As the number of therapies that target signaling pathways increase, it is expected that this technology will ensure that cancer patients will receive the most appropriate therapies and improve survival.
